🟢 Nasus Pharma is trading 8.1% up today after FDA clearance of NS002 IND

Nasus Pharma is trading 8.1% up at $3.68 after the FDA cleared its IND application for NS002, an investigational intranasal epinephrine powder for anaphylaxis.

• The clearance enables an FDA-approved clinical study.
• A pivotal study is planned for the fourth quarter of 2026, with topline data expected in the first quarter of 2027.
• The company positions NS002 as a needle-free alternative to EpiPen.